Company / Operating Cash Flow
United Therapeutics Operating Cash Flow History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Operating Cash Flow
$1.6B
FY2025
5-year range
$598.2M / $1.6B
FY2021-FY2025
Trend
+17.6%
vs FY2024
Sector context
#17 of 216
Health Care
What the data says
Among 216 Health Care companies, United Therapeutics is in the top 8% for operating cash flow. Operating Cash Flow has increased for 4 consecutive years, from $598M in FY2021 to $1.6B in FY2025.
Based on SEC 10-K filings.
$1.6B in FY2025 with a 5-year CAGR of +15.6%. Top quartile in the Health Care sector.
Improved from $978M to $1.6B over the past 2 years.
Health Care sector context is included.
Operating Cash Flow over time
Growth rates
- 3-Year CAGR
- +24.8%
- 5-Year CAGR
- +15.6%
- 10-Year CAGR
- -
Sector benchmark
Top 8% in Health CareTop 8% of 216This company $1.6B Sector average $658.7M
▼
+137.0% above sector average
Key checks
Key Insights
- United Therapeutics's operating cash flow has grown for 4 consecutive years.
- 5-year CAGR of +15.6%, indicating consistent growth.
- In FY2025, operating cash flow increased 17.6% year-over-year.
- Ranks #17 out of 216 companies in the Health Care sector.
Company context
Key Data Points
- Altman Z-Score 6.00 (safe zone, above 2.9 threshold)
- Strong profit margin: 40.6%
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Operating Cash FlowValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $1.6B | +17.6% |
| FY2024 | $1.3B | +35.7% |
| FY2023 | $978.0M | +21.9% |
| FY2022 | $802.5M | +34.2% |
| FY2021 | $598.2M | -20.8% |
| FY2020 | $755.7M | +465.8% |
| FY2019 | -$206.6M | -126.5% |
| FY2018 | $778.4M | +103.3% |
| FY2017 | $382.8M | -40.5% |
| FY2016 | $643.6M | +68.1% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026